OTC · Healthcare

LakeShore Biopharma Co., Ltd. (LSBCF)

As-reported financials and recent SEC filings for LakeShore Biopharma Co., Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$615.0M

Net income

$-100.0M

Net margin

-16.3%

Diluted EPS

$-5.22

ROE

-20.0%

P/E (TTM)

—

Market cap

—

Debt / equity

0.0×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2023	FY2023
Revenue	$615.0M	$573.4M	$687.2M	$502.9M	$257.0M
Gross profit	$507.2M	$455.7M	$533.8M	$385.9M	$197.4M
Operating income	$-86.3M	$-445.8M	$-139.4M	$-119.0M	$-125.8M
Net income	$-100.0M	$-433.5M	$-145.5M	$-106.0M	$-191.8M
Diluted EPS	$-5.22	$-40.54	$-23.55	$-17.10	$-31.00

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

SCHEDULE 13D/A2026-06-25

15-12G2026-06-24

S-8 POS2026-06-24

S-8 POS2026-06-24

SC 13E3/A2026-06-24

6-K2026-06-24

6-K2026-06-22

6-K2026-05-28

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on LSBCF

Search LakeShore Biopharma Co., Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.